The case for therapeutic overactivation of oncogenic signaling as a potential cancer treatment strategy

Cancer Cell. 2024 Jun 10;42(6):919-922. doi: 10.1016/j.ccell.2024.04.014. Epub 2024 May 23.

Abstract

Most targeted cancer drugs inhibit the oncogenic signals to which cancer cells are addicted. We discuss here a counterintuitive approach to cancer therapy, which consists of deliberate overactivation of the oncogenic signals to overload the stress responses of cancer cells. We discuss why such overactivation of oncogenic signaling, combined with perturbation of the stress response pathways, can be potentially effective in killing cancer cells, aiming to inspire further discussion and consideration.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Humans
  • Molecular Targeted Therapy / methods
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • Neoplasms* / metabolism
  • Oncogenes
  • Signal Transduction* / drug effects

Substances

  • Antineoplastic Agents